NCT05943093

Brief Summary

  • Study the expression level of H19 gene in the samples from ALL patients by real-time PCR.
  • Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
96

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2023

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2023

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

July 5, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 13, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

July 13, 2023

Status Verified

July 1, 2023

Enrollment Period

2 years

First QC Date

July 5, 2023

Last Update Submit

July 11, 2023

Conditions

Acute Lymphoid Leukemia

Outcome Measures

Primary Outcomes (1)

  • - Study the expression level of H19 gene in the samples from ALL patients by real-time PCR.

    baseline

Secondary Outcomes (1)

  • Correlate the expression level of H19 gene with the clinical presentation and laboratory data of those patients.

    baseline

Study Arms (2)

ALL patients

control group free from the disease

Eligibility Criteria

Age2 Months - 70 Years
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

newly diagnosed ALL patients

You may qualify if:

  • Newly diagnosed ALL patients.

You may not qualify if:

  • \- 1-Presence of other haematological disorders, history of other malignancies or relapsed ALL.
  • Patients under chemotherapy or radiotherapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Fatma Refaat Ibrahim

CONTACT

01032073035drfatmarefaat@gmail.com

Hosney Badrawy Hamed, professor

CONTACT

Badrawy@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

July 5, 2023

First Posted

July 13, 2023

Study Start

July 1, 2023

Primary Completion

July 1, 2025

Study Completion

August 1, 2025

Last Updated

July 13, 2023

Record last verified: 2023-07